J. Pérez-Gracia

J. García-Foncillas, J. Pérez-Gracia, A. Gúrpide, 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Synergistic effects of CTLA‐4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo

B. Sangro, I. Melero, S. Martín-Algarra, 2011, International journal of cancer.

The Dynamic Use of EGFR Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients

A. Patiño-García, G. Alkorta-Aranburu, J. Pérez-Gracia, 2019, Disease markers.

The Dynamic Use of EGFRMutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients

A. Patiño-García, G. Alkorta-Aranburu, J. Pérez-Gracia, 2019 .

Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4–1BB)

J. Zapata, I. Melero, M. Rodriguez-Ruiz, 2018, Oncoimmunology.

Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

B. Sangro, I. Melero, M. Rodriguez-Ruiz, 2014, Clinical Cancer Research.

Personalized Medicine and Imaging Serum Interleukin-8 Re fl ects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

B. Sangro, I. Melero, M. Rodriguez-Ruiz, 2014 .

Comparison of six commercial serum exosome isolation methods suitable for clinical laboratories. Effect in cytokine analysis

J. Pérez-Gracia, Álvaro González, B. Mateos, 2019, Clinical chemistry and laboratory medicine.

TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies

I. Melero, M. Rodriguez-Ruiz, J. Pérez-Gracia, 2019, Molecular Cancer Therapeutics.

Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research.

E. Carrasco, J. Pérez-Gracia, 2002, Gynecologic oncology.

Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC)

E. Gallardo, J. Maroto, B. Mellado, 2013, Clinical and Translational Oncology.

Immunotherapy and immunoescape in colorectal cancer.

I. Melero, J. Pérez-Gracia, I. Tirapu, 2007, World journal of gastroenterology.

CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity.

M. Carleton, K. Schalper, I. Melero, 2020, Immunity.

Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?

B. Sangro, I. Melero, J. Pérez-Gracia, 2009, Immunotherapy.

Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies

E. Gallardo, J. Pérez-Gracia, I. Durán, 2020, Clinical and Translational Oncology.

Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients

I. Melero, M. Rodriguez-Ruiz, J. Pérez-Gracia, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.

K. Schalper, I. Melero, M. Rodriguez-Ruiz, 2016, Cancer research.

Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer

I. Melero, J. Pérez-Gracia, A. Arina, 2007, Expert opinion on biological therapy.

[Treatment of prostate cancer according to life expectancy, comorbidity and clinical practice guidelines].

J. Pérez-Gracia, J. P. Fusco, A. Gúrpide, 2015, Anales del sistema sanitario de Navarra.

Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer

I. Tusquets, E. Carrasco, A. Font, 2002, Anti-cancer drugs.

Circulating Tumor Cells as a Biomarker of Survival and Response to Radium‐223 Therapy: Experience in a Cohort of Patients With Metastatic Castration‐Resistant Prostate Cancer

J. Carles, B. Mellado, J. Pérez-Gracia, 2018, Clinical genitourinary cancer.

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

J. Carles, E. Gallardo, B. Mellado, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours

G. Restovic, J. Pérez-Gracia, I. Durán, 2013, Clinical and Translational Oncology.

Interleukin-15 liver gene transfer increases the number and function of IKDCs and NK cells

J. Prieto, I. Melero, S. Ferrini, 2008, Gene Therapy.

Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies.

I. Melero, J. Pérez-Gracia, O. Murillo, 2008, Trends in pharmacological sciences.

IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).

J. Rosenberg, J. Bellmunt, D. Petrylak, 2016 .

Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication.

J. Prieto, I. Melero, J. Pérez-Gracia, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma.

R. Herbst, D. Petrylak, D. Ferry, 2017 .

Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors

I. Melero, M. Rodriguez-Ruiz, P. López-Casas, 2020, Science Translational Medicine.

Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism

I. Melero, M. Rodriguez-Ruiz, J. Pérez-Gracia, 2014, Journal of Immunotherapy for Cancer.

Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.

E. Gallardo, B. Mellado, J. Bellmunt, 2017, The Lancet. Oncology.

Randomized phase II study of maintenance vinflunine versus best supportive care after first line chemotherapy in patients with advanced urothelial carcinoma : The MAJA study ( SOGUG 2011 / 02 )

Begoña, E. Gallardo, J. Bellmunt, 2017 .

ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy

G. Bodoky, J. Douillard, A. Awada, 2020, ESMO Open.

Neoadjuvant immunotherapy in non-small cell lung cancer: the sooner the better?

I. Melero, J. Pérez-Gracia, M. Sanmamed, 2018, Translational lung cancer research.

Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma.

T. Powles, C. Sternberg, J. Rosenberg, 2020, European urology focus.

Circulating melanoma exosomes as diagnostic and prognosis biomarkers.

J. Pérez-Gracia, Álvaro González, E. Alegre, 2016, Clinica chimica acta; international journal of clinical chemistry.

The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFNγ

J. Prieto, I. Melero, J. Pérez-Gracia, 2007, International journal of cancer.

Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma

I. Melero, J. Pérez-Gracia, A. Arina, 2008, Clinical Cancer Research.

Immunogenic Cell Death and Cross-Priming Are Reaching the Clinical Immunotherapy Arena

I. Melero, J. Pérez-Gracia, A. Arina, 2006, Clinical Cancer Research.

Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.

T. Choueiri, M. Fishman, M. Harrison, 2014 .

Radium-223 international early access program: results from the Spanish subset.

J. Carles, B. Mellado, E. Esteban, 2018, Future oncology.

PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210).

R. Bourgon, P. Hegde, T. Powles, 2016 .

579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC)

F. Saad, M. Burotto, L. Lacombe, 2021, Annals of Oncology.

Randomized Pharmacokinetic Study Comparing Subcutaneous and Intravenous Palonosetron in Cancer Patients Treated with Platinum Based Chemotherapy

F. Grimá, J. Pérez-Gracia, J. López-Picazo, 2014, PloS one.

Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer.

J. Pérez-Gracia, I. Gil-Bazo, J. López-Picazo, 2009, World journal of gastroenterology.

Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung cancer: two case reports and a review of the literature.

J. García-Foncillas, J. Pérez-Gracia, J. López-Picazo, 2005, Clinical lung cancer.

First-line treatment with sunitinib monotherapy in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy: Pretreatment levels of IL8 and Hounsfield units as predictors of clinical benefit.

J. Carles, E. Gallardo, J. Maroto, 2010 .

Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade

S. Vicent, F. Lecanda, J. Pérez-Gracia, 2020, Nature Cancer.

Non-O1 Vibrio cholerae inguinal skin and soft tissue infection with bullous skin lesions in a patient with a penis squamous cell carcinoma

J. Pérez-Gracia, J. Yuste, J. Leiva, 2009, Annals of Clinical Microbiology and Antimicrobials.

Paradigms on Immunotherapy Combinations with Chemotherapy.

I. Melero, M. Rodriguez-Ruiz, J. Pérez-Gracia, 2021, Cancer discovery.

Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.

M. Hidalgo, K. Schalper, I. Melero, 2015, Cancer research.

Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.

I. Melero, M. Rodriguez-Ruiz, J. Pérez-Gracia, 2015, Seminars in oncology.

Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

Hongyu Zhao, M. Carleton, K. Schalper, 2020, Nature Medicine.

Interleukin-8 in cancer pathogenesis, treatment and follow-up.

K. Schalper, I. Melero, M. Rodriguez-Ruiz, 2017, Cancer treatment reviews.

Unnecessary test ordering in clinical trials: human chorionic gonadotropin as an example

J. Pérez-Gracia, M. Sanmamed, E. Alegre, 2020 .

Direct Effects of Type I Interferons on Cells of the Immune System

Ana Rouzaut, I. Melero, J. Pérez-Gracia, 2011, Clinical Cancer Research.

Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs)

I. Melero, J. Pérez-Gracia, P. Berraondo, 2016, Clinical Cancer Research.

A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum‐resistant ovarian cancer

B. Mellado, G. Scambia, J. Pérez-Gracia, 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

I. Melero, M. Rodriguez-Ruiz, J. Pérez-Gracia, 2019, Nature.

A novel protein‐based prognostic signature improves risk stratification to guide clinical management in early‐stage lung adenocarcinoma patients

I. Wistuba, C. Behrens, M. Pajares, 2018, The Journal of pathology.

Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti–PD‐1 and Anti‐CD137 Monoclonal Antibodies

I. Melero, M. Rodriguez-Ruiz, M. Larrayoz, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

K. Schalper, I. Melero, M. Rodriguez-Ruiz, 2019, Nature Medicine.

5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death Ligand 1-Positive Advanced Non-Small-Cell Lung Cancer.

R. Herbst, S. Novello, P. Baas, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis

R. Herbst, K. Syrigos, D. Rimm, 2019, Clinical Cancer Research.

Quantitative Cell-Free Circulating BRAF Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors

R. Zárate, J. Pérez-Gracia, Álvaro González, 2014 .

[Specialized dendritic cells in cross-presentation of exogenous antigens to cytotoxic T lymphocytes].

I. Melero, J. Pérez-Gracia, C. Alfaro, 2013, Anales del sistema sanitario de Navarra.

Polly Matzinger's “danger model” finds its predicted danger-denoting self moieties

I. Melero, J. Pérez-Gracia, S. Hervás-Stubbs, 2008 .

Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco‐induced lung cancer

J. Benítez, A. González-Neira, G. Pita, 2018, Cancer medicine.

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

R. Halaban, K. Schalper, M. Sznol, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma

J. Carles, M. Climent, E. Gallardo, 2014, PloS one.

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Y. Shentu, R. Herbst, M. Ahn, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes.

J. Pérez-Gracia, R. Pio, M. Lozano, 2011, The oncologist.

Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma

A. González-Neira, G. Pita, I. Melero, 2021, Translational lung cancer research.

Designing clinical studies for biomarker discovery: The Design criteria

I. Melero, A. Patiño-García, J. Pérez-Gracia, 2020 .

Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer

S. Minucci, I. Melero, A. Patiño-García, 2019, International journal of cancer.

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.

T. Powles, J. Rosenberg, B. Nelson, 2017, European urology.

Identification through genome-wide association study (GWAS) of single nucleotide polymorphisms (SNPs) associated with extreme phenotypes of tobacco-induced non-small cell lung cancer (NSCLC) risk.

J. Benítez, A. González-Neira, G. Pita, 2014 .

Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer.

P. Massion, M. Pajares, J. de-Torres, 2013, Journal of the National Cancer Institute.

Cancer protective mutations: looking for the needle in the haystack

J. Pérez-Gracia, María Gloria Ruiz-Ilundáin, 2001, Revista de Oncología.

Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value

M. Rodriguez-Ruiz, A. Patiño-García, M. Pajares, 2016, Tumor Biology.

SEOM clinical guideline for treatment of kidney cancer (2017)

E. Gallardo, J. Pérez-Gracia, E. Grande, 2017, Clinical and Translational Oncology.

Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study

J. Rosenberg, D. Petrylak, A. Necchi, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC)

J. Pérez-Gracia, A. Antón, P. Martín-Duque, 2012, Clinical and Translational Oncology.

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

P. Ross-Macdonald, T. Choueiri, M. Fishman, 2016, Clinical Cancer Research.

A Phase I Pharmacologic Study of Necitumumab (imc-11f8), a Fully Human Igg1 Monoclonal Antibody the Hif-1␣ Hypoxia Response in Tumor-infi Ltrating T Lymphocytes Induces Functional Cd137 (4-1bb) for Immunotherapy

I. Melero, J. Aragonés, J. Pérez-Gracia, 2022 .

[The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].

J. Prieto, I. Melero, J. Pérez-Gracia, 2006, Anales del sistema sanitario de Navarra.

6 The Role of extreme phenotype selection in cancer research

E. Carrasco, J. Pérez-Gracia, I. García-Ribas, 2002 .

Cytokines in clinical cancer immunotherapy

I. Melero, M. Rodriguez-Ruiz, J. Pérez-Gracia, 2018, British Journal of Cancer.

Toxic Epidermal Necrolysis Related to Pemetrexed and Carboplatin with Vitamin B12 and Folic Acid Supplementation for Advanced Non-Small Cell Lung Cancer

J. Bosch-Barrera, J. García-Foncillas, J. Pérez-Gracia, 2009, Oncology Research and Treatment.

Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma.

J. Pérez-Gracia, U. A. Herranz, Susana Hernando-Polo, 2020, Clinical genitourinary cancer.

Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study.

R. Herbst, S. Novello, G. Ceresoli, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.

W. Schultze‐Seemann, J. Nippgen, B. Sautois, 2019, European journal of cancer.

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

I. Melero, M. Rodriguez-Ruiz, J. Pérez-Gracia, 2019, Nature.

Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy

I. Melero, J. Pérez-Gracia, D. Sancho, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A model based on the quantification of complement C4c, CYFRA 21–1 and CRP exhibits high specificity for the early diagnosis of lung cancer

P. Massion, J. Pérez-Gracia, Álvaro González, 2021, Translational research : the journal of laboratory and clinical medicine.

Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array

I. Melero, F. Guillén-Grima, J. Pérez-Gracia, 2009, British Journal of Cancer.

Orchestrating immune check-point blockade for cancer immunotherapy in combinations.

I. Melero, M. Rodriguez-Ruiz, J. Pérez-Gracia, 2014, Current opinion in immunology.

Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).

Joaquim Bellmunt, Joan Carles, Jordi Rubió, 2010, The Lancet. Oncology.

Cardiotrophin-1 determines liver engraftment of syngenic colon carcinoma cells through an immune system-mediated mechanism

C. Ortiz de Solórzano, I. Melero, J. Pérez-Gracia, 2012, Oncoimmunology.

[Small-cell lung cancer].

J. García-Foncillas, J. Pérez-Gracia, J. López-Picazo, 2007, Revista de medicina de la Universidad de Navarra.

Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy.

J. García-Foncillas, J. Pérez-Gracia, I. Gil-Aldea, 2007, The oncologist.

Carcinoma-Derived Interleukin-8 Disorients Dendritic Cell Migration Without Impairing T-Cell Stimulation

I. Melero, J. Pérez-Gracia, Álvaro González, 2011, PloS one.

Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes.

P. Ross-Macdonald, T. Choueiri, M. Fishman, 2015 .

A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis

I. Melero, M. Rodriguez-Ruiz, F. Rotellar, 2018, Journal of Immunotherapy for Cancer.

Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy.

I. Melero, J. Pérez-Gracia, D. Sancho, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes.

I. Melero, J. Pérez-Gracia, S. Hervás-Stubbs, 2011, Cancer research.

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

I. Melero, J. Pérez-Gracia, S. Hervás-Stubbs, 2009, British Journal of Cancer.

Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study

M. Climent, B. Mellado, J. Pérez-Gracia, 2019, Medical Oncology.

A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results.

R. Herbst, J. Bendell, D. Ferry, 2016 .

Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis.

John D Lambris, C. Ortiz de Solórzano, S. Vicent, 2021, Cancer letters.

Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes

J. Bellmunt, J. Pérez-Gracia, A. Rodríguez-Vida, 2018, Clinical Cancer Research.

Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)

R. Herbst, L. Paz-Ares, J. Bendell, 2016 .

Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–Positive NSCLC.

Y. Shentu, R. Herbst, M. Ahn, 2016 .

Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group.

B. Mellado, J. García-Donas, J. Pérez-Gracia, 2022, Clinical genitourinary cancer.

High‐dose mitoxantrone and cyclophosphamide without stem cell support in patients with high‐risk and advanced breast carcinoma

E. Esteban, J. Pérez-Gracia, R. Colomer, 2001 .

Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies.

I. Melero, M. Rodriguez-Ruiz, J. Pérez-Gracia, 2017, Brachytherapy.

71 Whole exome sequencing of individuals presenting extreme phenotypes of high and low-risk of developing tobacco-induced lung adenocarcinoma: relevance of immune and DNA-repair related pathways

A. Patiño-García, J. Pérez-Gracia, A. Gúrpide, 2020 .

Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors

I. Melero, M. Rodriguez-Ruiz, J. Pérez-Gracia, 2020, Oncoimmunology.

Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control

I. Melero, Helena Escuin-Ordinas, M. Rodriguez-Ruiz, 2023, Journal for ImmunoTherapy of Cancer.

External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome.

J. Pérez-Gracia, I. Gil-Bazo, M. Gaztañaga, 2012, International journal of radiation oncology, biology, physics.

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.

Y. Shentu, R. Herbst, M. Ahn, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab

P. Ross-Macdonald, T. Choueiri, M. Fishman, 2015, Journal of Immunotherapy for Cancer.

Assessment of the value of confirming responses in clinical trials in oncology.

J. García-Foncillas, E. Carrasco, J. Pérez-Gracia, 2005, European journal of cancer.

Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Outcomes by prior therapy.

T. Powles, J. Rosenberg, A. Necchi, 2017 .

Variations in Molecular Profile in NSCLC Can Be Analyzed Using Cytological Samples

J. Pérez-Gracia, M. Lozano, J. Zulueta, 2015, International journal of surgical pathology.

Changes in serum IL8 levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients

R. Halaban, M. Sznol, I. Melero, 2016 .

Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes.

J. Pérez-Gracia, I. Gil-Bazo, R. Martínez-Monge, 2016, Brachytherapy.

Factors associated with better overall survival (OS) in patients with previously treated, PD-L1–expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010.

R. Herbst, M. Ahn, E. Felip, 2017 .

Pazopanib-induced asymptomatic radiological acute pancreatitis: A case report

C. Rolfo, J. Pérez-Gracia, I. Gil-Bazo, 2017, Molecular and clinical oncology.

Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors.

I. Melero, M. Rodriguez-Ruiz, P. López-Casas, 2018, Annals of Oncology.

A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL).

H. Kohrt, J. Wolchok, F. Hodi, 2013 .

Dendritic Cells Take up and Present Antigens from Viable and Apoptotic Polymorphonuclear Leukocytes

I. Melero, J. Pérez-Gracia, Álvaro González, 2011, PloS one.

Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with acquired resistance to erlotinib.

J. Weissman, R. Stahel, A. Uzilov, 2013 .

Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.

Y. Shentu, R. Herbst, M. Ahn, 2016 .

Phase II randomized study of first line avelumab with carboplatin-gemcitabine versus carboplatin-gemcitabine alone in patients with metastatic urothelial carcinoma ineligible for cisplatin-based therapy.

M. Climent, B. Mellado, J. Bellmunt, 2018 .

Pathological vertebral fracture after stereotactic body radiation therapy for lung metastases. Case report and literature review.

M. Rodriguez-Ruiz, J. Pérez-Gracia, I. Gil-Bazo, 2012, Radiation oncology.

Dual modulation of MCL-1 and mTOR determines the response to sunitinib

B. Teh, S. Minucci, C. Mercurio, 2017, The Journal of clinical investigation.

Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma

J. García-Foncillas, J. Pérez-Gracia, M. Santisteban, 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.

A. Tres, J. Mayordomo, V. Guillem, 2001, Journal of the National Cancer Institute.

Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population

X. G. Del Muro, J. Pérez-Gracia, D. Castellano, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Cytokines in clinical cancer immunotherapy

I. Melero, M. Rodriguez-Ruiz, J. Pérez-Gracia, 2018, British Journal of Cancer.

Functional expression of CD137 (4-1BB) on T helper follicular cells

I. Melero, M. Rodriguez-Ruiz, J. Pérez-Gracia, 2015, Oncoimmunology.

Annals of Clinical Microbiology and Antimicrobials Open Access Non-o1 Vibrio Cholerae Inguinal Skin and Soft Tissue Infection with Bullous Skin Lesions in a Patient with a Penis Squamous Cell Carcinoma

J. Pérez-Gracia, J. Yuste, J. Leiva, 2022 .

Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study

T. Powles, J. Rosenberg, A. Necchi, 2016 .